{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:18:12Z","timestamp":1789417092137,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)\u2013negative, antibody to hepatitis B core antigen (anti\u2010HBc)\u2013positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not been prospectively studied. HBsAg\u2010negative, anti\u2010HBc\u2013positive patients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 weeks. The primary endpoint was HBV reactivation, defined as detectable HBV DNA (\u226510 IU\/mL). Secondary endpoints included overall survival, HBsAg positivity, and changes in liver biochemistry and antibody to HBsAg levels. Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg\u2010negative, anti\u2010HBc\u2013positive, of whom 62 were recruited and monitored for a median of 48 (4\u2010104) weeks. The 2\u2010year cumulative HBV DNA detectability rate was 40.8%, occurring at a median of 44 (8\u2010100) weeks. Multivariate analysis showed that age \u226550 years (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004, hazard ratio = 8.2) and chronic graft\u2010versus\u2010host disease (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.010, hazard ratio = 5.3) were significantly associated with HBV reactivation. Other clinical parameters, including baseline antibody to HBsAg status, serial changes in antibody to HBsAg levels, and donor serology, were not associated with HBV reactivation. Patients &lt;50 years old and without chronic graft\u2010versus\u2010host disease, compared with the remaining patient cohort, had a significantly lower 2\u2010year cumulative HBV reactivation rate (5.6% versus 65.0%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004). Entecavir successfully suppressed HBV DNA to undetectable levels, with no cases developing biochemical hepatitis. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: HBsAg\u2010negative, anti\u2010HBc\u2013positive patients had a high rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation including age \u226550 years and chronic graft\u2010versus\u2010host disease; treatment strategies based on these parameters may prevent HBV reactivation and subsequent complications. (ClinicalTrials.gov identifier NCT01481649.) (H<jats:sc>epatology<\/jats:sc> 2017;65:1451\u20101461).<\/jats:p>","DOI":"10.1002\/hep.29022","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T00:09:09Z","timestamp":1482883749000},"page":"1451-1461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":98,"title":["Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study"],"prefix":"10.1097","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai\u2010Kay","family":"Seto","sequence":"first","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"},{"name":"State Key Laboratory for Liver Research,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Sau\u2010Yan","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Yan","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny Ka\u2010Ho","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"},{"name":"State Key Laboratory for Liver Research,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"},{"name":"State Key Laboratory for Liver Research,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Sze\u2010Hang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuk\u2010Fai","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.Y.","family":"Lau","sequence":"additional","affiliation":[{"name":"School of Public Health,The University of Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka\u2010Shing","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert K.W.","family":"Lie","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching\u2010Lung","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"},{"name":"State Key Laboratory for Liver Research,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok\u2010Lam","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man\u2010Fung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong, Queen Mary Hospital,Hong Kong"},{"name":"State Key Laboratory for Liver Research,The University of Hong Kong, Queen Mary Hospital,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"hep29022-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"hep29022-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cgh.2006.05.027","article-title":"Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention","volume":"4","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep29022-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","year":"2008","journal-title":"Ann Intern Med"},{"key":"hep29022-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","year":"2007","journal-title":"J Hepatol"},{"key":"hep29022-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0168-8278(00)80134-8","article-title":"Occult hepatitis B virus after acute self\u2010limited infection persisting for 30 years without sequence variation","volume":"33","year":"2000","journal-title":"J Hepatol"},{"key":"hep29022-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","year":"2008","journal-title":"Gastroenterology"},{"key":"hep29022-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab\u2010containing chemotherapy for lymphoma: a prospective study","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"hep29022-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1086\/496924","article-title":"Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B\u2013immune patient: case report and review of the literature","volume":"41","year":"2005","journal-title":"Clin Infect Dis"},{"key":"hep29022-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2010.70","article-title":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT","volume":"46","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"hep29022-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"hep29022-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"21455","DOI":"10.3390\/ijms151121455","article-title":"Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment","volume":"15","year":"2014","journal-title":"Int J Mol Sci"},{"key":"hep29022-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/1469-0691.12611","article-title":"Hepatitis B reactivation in HBsAg\u2010negative\/HBcAb\u2010positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome","volume":"20","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"hep29022-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.bbmt.2011.04.006","article-title":"Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus","volume":"17","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"hep29022-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2009.11.009","article-title":"Epidemiology of hepatitis B and C viruses: a global overview","volume":"14","year":"2010","journal-title":"Clin Liver Dis"},{"key":"hep29022-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/j.1537-2995.2010.03056.x","article-title":"Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors","volume":"51","year":"2011","journal-title":"Transfusion"},{"key":"hep29022-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MEG.0b013e328347322b","article-title":"Prevalence of hepatitis B in the southeast of China: a population\u2010based study with a large sample size","volume":"23","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep29022-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1440-1746.2007.05010.x","article-title":"Highly endemic hepatitis B infection in rural Vietnam","volume":"22","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"hep29022-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: a global perspective","volume":"303","year":"2010","journal-title":"JAMA"},{"key":"hep29022-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft\u2010versus\u2010host disease: I. Diagnosis and staging working group report","volume":"11","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"hep29022-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First\u2010 and second\u2010line systemic treatment of acute graft\u2010versus\u2010host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"hep29022-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft\u2010versus\u2010host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft\u2010versus\u2010Host Disease: IV. Response Criteria Working Group report","volume":"12","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"hep29022-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep29022-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","year":"2001","journal-title":"Gastroenterology"},{"key":"hep29022-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","year":"2004","journal-title":"Hepatology"},{"key":"hep29022-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","article-title":"Long\u2010term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance","volume":"42","year":"2005","journal-title":"J Hepatol"},{"key":"hep29022-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft\u2010versus\u2010host disease","volume":"124","year":"2014","journal-title":"Blood"},{"key":"hep29022-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab\u2010associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"hep29022-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","article-title":"Viral hepatitis B","volume":"362","year":"2003","journal-title":"Lancet"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201705000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T01:00:58Z","timestamp":1729213258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201705000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29022","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]},"assertion":[{"value":"2016-07-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}